[ad_1]
LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.
Medscape Medical News
[ad_2]
Source link : https://www.medscape.com/viewarticle/belzutifan-plus-pembro-approved-adjuvant-rcc-2026a1000jxb?src=rss
Author :
Publish date : 2026-06-12 20:35:00
Copyright for syndicated content belongs to the linked Source.